Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Adenocarcinoma of the Stomach 1

Interventions

Fluorouracil 18Oxaliplatin 17Capecitabine 16Leucovorin 13Cisplatin 12Gemcitabine 11Drug Therapy 11Irinotecan 10Radiosurgery 9Cetuximab 9Bevacizumab 9pembrolizumab 8Docetaxel 8Everolimus 7spartalizumab 6Sunitinib 6Radiotherapy 6Paclitaxel 6Neoadjuvant Therapy 6Cyclophosphamide 6Trastuzumab 5S 1 (combination) 5Nivolumab 5Immunotherapy 5Immune Checkpoint Inhibitors 5Chemotherapy, Adjuvant 5Carboplatin 5palbociclib 4manganese chloride 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasm Metastasis × GC1118 × Clear all
NCT02352571 2016-07-06

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

GC Biopharma Corp

Phase 1 Unknown
72 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡